Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance

A 12-Week Randomized, Double-Blinded Study to Evaluate the Effects of Daily Oral Doses of BMS-741672 in Drug-Naive Type 2 Diabetic Patients

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00699790

Enrollment

Registered

2008-06-18

Start date

2009-02-28

Completion date

2009-12-31

Last updated

2015-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Diabetes, NOS

Brief summary

The purpose of the study is to determine whether a CCR2 antagonist (BMS-741672) improves glucose homeostasis in drug-naive type 2 diabetic patients

Interventions

DRUGCCR2 Antagonist

Tablets, Oral, 50 mg, once daily, 12 weeks

DRUGPlacebo

Tablets, Oral, 0mg, once daily, 12 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Drug-naive Type 2 diabetics with a screening HbA1c of ≥ 7.5% and ≤ 10% * Screening FPG ≥ 140 mg/dL and ≤ 220 mg/dL * BMI ≤ 40 kg/m2

Exclusion criteria

* Active tuberculosis * Symptoms of poorly controlled diabetes * History of diabetic ketoacidosis * Significant cardiovascular history or gastrointestinal disorders * History of unstable or rapidly progressing renal disease * Active liver disease and/or significant abnormal liver function * Abnormal chest x-ray at screening indicative of tuberculosis or other infection

Design outcomes

Primary

Measure	Time frame
Change in HbA1c	after 12 weeks of treatment

Secondary

Measure	Time frame
Other glycemic, atherosclerosis, lipid and mechanism-based biomarkers will be measured	throughout the 12 weeks of treatment

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026